- Conditions
- Kidney Cancer
- Interventions
- PEG-interferon alfa-2b, gefitinib
- Biological · Drug
- Lead sponsor
- California Cancer Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 46
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatitis C
- Interventions
- Interferon Alfacon-1 and Ribavirin
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infection, Hepatitis C Infection
- Interventions
- Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
- Conditions
- Chronic Hepatitis C
- Interventions
- valopicitabine, Pegylated Interferon Alfa
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 175 participants
- Timeline
- Started 2005
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
- Conditions
- Pediatric Immuno-Tolerant Chronic Hepatitis B
- Interventions
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
- Conditions
- Hepatitis C Infection, HIV Infection
- Interventions
- Nitazoxanide With Pegylated Interferon And Ribavirin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Infection
- Interventions
- Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C
- Interventions
- Infergen and ribavirin
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Harrisburg, North Carolina + 1 more
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- St. Luke's Hospital and Health Network, Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Buffalo, New York • Bethlehem, Pennsylvania + 1 more
- Conditions
- Hepatitis C, Hepatitis
- Interventions
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Hepatitis C, Genotype 1
- Interventions
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Hepatitis C Virus
- Interventions
- Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- HIV, Hepatitis C, Infections
- Interventions
- Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 4
- States / cities
- Lancaster, California • Los Angeles, California
- Conditions
- Hepatitis B
- Interventions
- Entecavir and peginterferon
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- San Francisco, California • Baltimore, Maryland • Minneapolis, Minnesota + 3 more
- Conditions
- Chronic Hepatitis C
- Interventions
- GS-5885, GS-9451, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Lymphoma, Small Intestine Cancer
- Interventions
- pegylated interferon alfa
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis Delta Virus
- Interventions
- Lonafarnib, Ritonavir, PEG IFN-alfa-2a, Placebo Lonafarnib, Placebo Ritonavir
- Drug
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 18
- States / cities
- Fresno, California • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
- Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
- Conditions
- Hepatitis C
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C
- Interventions
- BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more